search
Back to results

Use of PillCam ESO2 in Triaging Patients Present With Upper GIB

Primary Purpose

Upper Gastrointestinal Bleeding

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PillCam ESO2
Sponsored by
Chinese University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Upper Gastrointestinal Bleeding focused on measuring Gastrointestinal bleeding, emergency department, PillCam ESO2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena

Exclusion Criteria:

  • UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy,
  • UGIB with fresh hematemesis requiring urgent endoscopy
  • dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation,
  • prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery.
  • presence of an electromedical device (pacemaker or internal cardiac defibrillator),
  • altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent.
  • Allergy to Maxolon
  • Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes
  • Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    No Intervention

    Arm Label

    Capsule group: PillCam ESO2

    Standard group

    Arm Description

    Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion

    Perform standard esophagogastroduodenoscopy

    Outcomes

    Primary Outcome Measures

    The number of patients requiring hospital admission
    Patients with evidence of significant bleeding will be admitted to ward and receive early endoscopy (EGD)

    Secondary Outcome Measures

    Clinical rebleeding
    Recurrent GI bleeding
    Mortality
    Death rate
    Cost of management in different strategies
    Cost of management in different strategies
    Comparing the effectiveness of CE against Glasgow Blatchford score in identifying patients with UGIB that may require endoscopic intervention
    Using Glasgow Blatchford score

    Full Information

    First Posted
    May 12, 2015
    Last Updated
    April 23, 2017
    Sponsor
    Chinese University of Hong Kong
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02446678
    Brief Title
    Use of PillCam ESO2 in Triaging Patients Present With Upper GIB
    Official Title
    The Use Of PillCam Esophagus In Triaging Patients Presented With Upper Gastrointestinal Bleeding
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2017
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2013 (undefined)
    Primary Completion Date
    April 2015 (Actual)
    Study Completion Date
    April 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Chinese University of Hong Kong

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Background Patients presented to hospital with coffee ground vomiting and black stool may not be actually having upper gastrointestinal bleeding (UGIB) Hospital admission can be avoided if serious UGIB can be excluded To date, the only useful tool to triage patient for hospital admission in UGIB is by using clinical score such as Rockall score or Blatchford score These scores are cumbersome and only exclude the most benign cases, but they are not useful in differentiating those who needs intervention In our pilot study, investigators found that capsule endoscopy can be used to identify patients with fresh blood and real coffee ground substance in the stomach and it is superior to nasogastric tube Most of UGI lesions leading to bleeding can be diagnosed by capsule endoscopy Objectives The current study is designed to validate capsule endoscopy is an effective method in identifying patients with UGIB to study whether the capsule endoscopy can reduce requirement of hospital admission in patients with suspected UGIB to study if capsule endoscopy can help to identify patients with UGIB that may require urgent (within 24 hours) endoscopy and intervention to study the cost-effectiveness of capsule endoscopy being used as a triaging tool in the management of UGIB to compare the effectiveness of capsule endoscopy against Blatchford score in identifying patients with UGIB that may require endoscopic intervention.
    Detailed Description
    Hypothesis PillCam Esophagus is effective in identifying genuine UGIB and hence able to reduce hospital admission due to unsubstantiated UGIB cases Methodology Patients presented to the Accident & Emergency Department (A&ED) of the Prince of Wales Hospital Hong Kong with symptoms suggestive of UGIB will be recruited into this study Patients will receive the following tests Complete blood count Coagulation profile Renal and liver function tests Hourly BP, Pulse up to 6 hours Glasgow Blatchford score calculated on admission Randomization Capsule Group: Capsule Endoscopy (CE) by using PillCam Esophagus (PillCam ESO) OR Standard group: Hospitalization and Standard of Care The video in capsule endoscopy will be read by trained personnel who have undergone at least one hour lecture about realtime reviewing. Legally a patient has to be signed off by a clinician within 6 hours. The finding of fresh blood or coffee ground will be documented. Upper GI pathology that may lead to bleeding will also be recorded. Capsule Endoscopy (CE) After confirming patient has been fasted for at least 5 hours, the subject ingested the PillCam® ESO 2 (Given Imaging Ltd., Yoqneam, Israel) (PillCam ESO) using the Simplified Ingestion Procedure. Thirty to sixty minutes prior to capsule ingestion, each subject received a single dose of intravenous Maxolon 10mg. Intravenous Maxolon, through its motilin receptor agonist effect, has been shown to promote gastric motility and improve visualization of the gastric mucosa at endoscopy. Moreover, use of Maxolon was thought to facilitate the capsule entering the duodenum. Using the REAL time viewer, UGI tract images (esophagus to the second portion of the duodenum) were obtained in real time at the patient's bedside. The video images that are transmitted by the PillCam ESO 2 are displayed in real time on the tablet computer screen. Each subject is also fitted with and wore the standard CE sensor array and data recorder so that a full-length CE video recording can be obtained for subsequent capsule workstation downloading and complete review. Other demographic data and parameters for Blatchford score calculation will be collected. 10 ml of blood will be taken for routine blood checking. Patients will receive standard care according to EGD findings.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Upper Gastrointestinal Bleeding
    Keywords
    Gastrointestinal bleeding, emergency department, PillCam ESO2

    7. Study Design

    Primary Purpose
    Screening
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    68 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Capsule group: PillCam ESO2
    Arm Type
    Active Comparator
    Arm Description
    Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
    Arm Title
    Standard group
    Arm Type
    No Intervention
    Arm Description
    Perform standard esophagogastroduodenoscopy
    Intervention Type
    Device
    Intervention Name(s)
    PillCam ESO2
    Intervention Description
    Capsule endoscopy
    Primary Outcome Measure Information:
    Title
    The number of patients requiring hospital admission
    Description
    Patients with evidence of significant bleeding will be admitted to ward and receive early endoscopy (EGD)
    Time Frame
    24 hours
    Secondary Outcome Measure Information:
    Title
    Clinical rebleeding
    Description
    Recurrent GI bleeding
    Time Frame
    30 days
    Title
    Mortality
    Description
    Death rate
    Time Frame
    30 days
    Title
    Cost of management in different strategies
    Description
    Cost of management in different strategies
    Time Frame
    One year
    Title
    Comparing the effectiveness of CE against Glasgow Blatchford score in identifying patients with UGIB that may require endoscopic intervention
    Description
    Using Glasgow Blatchford score
    Time Frame
    30 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Individual aged ≥ 18 years presenting to the emergency department with acute, overt UGIB defined as coffee ground vomiting and/or melena Exclusion Criteria: UGIB with hemodynamic shock (BP<90mmHg and pulse>120 per minutes) requiring urgent endoscopy, UGIB with fresh hematemesis requiring urgent endoscopy dysphagia, odynophagia, swallowing disorder, Zencker's diverticulum, suspected bowel obstruction or bowel perforation, prior bowel obstruction, gastroparesis or known gastric outlet obstruction, Crohn's disease, past GI tract surgery. presence of an electromedical device (pacemaker or internal cardiac defibrillator), altered mental status (e.g., hepatic encephalopathy) that would limit patient ability in swallowing the capsule, pregnancy and/or lactating, allergy to conscious sedation medications, allergy to Maxolon, unwillingness to swallow the capsule, patient expected to undergo Magnetic Resonance Imaging examination within 7 days of ingesting the capsule, patient on medications that may coat the upper GI tract such as antacids or sucralfate, or inability to provide written informed consent. Allergy to Maxolon Patients with known Esophageal Varices or Gastric Varices with or without prior bleeding episodes Known upper/ lower GI cancer (eg, cancer of esophagus, stomach, small bowel, colon) or hepatocellular carcinoma or pancreatic cancer
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jessica Y.L. Ching, MPH
    Organizational Affiliation
    Chinese University of Hong Kong
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    27156655
    Citation
    Sung JJ, Tang RS, Ching JY, Rainer TH, Lau JY. Use of capsule endoscopy in the emergency department as a triage of patients with GI bleeding. Gastrointest Endosc. 2016 Dec;84(6):907-913. doi: 10.1016/j.gie.2016.04.043. Epub 2016 May 6.
    Results Reference
    derived

    Learn more about this trial

    Use of PillCam ESO2 in Triaging Patients Present With Upper GIB

    We'll reach out to this number within 24 hrs